CIK 0001400118 · <br>Emerging growth company
Sagimet Biosciences Inc.
Sign in to watch- Ticker
- SGMT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 205991472
- Phone
- (650) 561-8600
- Business address
- 950 TOWER LANE, STE 1500, FOSTER CITY, CA, 94404
- Former names
- 3-V Biosciences, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-07-18 | Rozek Elizabeth General Counsel and CCO | Returned to the company · Stock Option (Right to Buy) | −242,142 | 0 | ||
| 2023-07-18 | Rozek Elizabeth General Counsel and CCO | Grant or award · Stock Option (Right to Buy) | +242,142 | 242,142 | ||
| 2023-07-18 | Rodgers Richard J Director | Returned to the company · Stock Option (Right to Buy) | −1,976 | 0 | ||
| 2023-07-18 | Rodgers Richard J Director | Grant or award · Stock Option (Right to Buy) | +1,976 | 1,976 | ||
| 2023-07-18 | Rodgers Richard J Director | Returned to the company · Stock Option (Right to Buy) | −23,216 | 0 | ||
| 2023-07-18 | Rodgers Richard J Director | Grant or award · Stock Option (Right to Buy) | +23,216 | 23,216 | ||
| 2023-07-18 | Rodgers Richard J Director | Returned to the company · Stock Option (Right to Buy) | −23,839 | 0 | ||
| 2023-07-18 | Rodgers Richard J Director | Grant or award · Stock Option (Right to Buy) | +23,839 | 23,839 | ||
| 2023-07-18 | Rimac Anthony M Chief Operating Officer | Returned to the company · Stock Option (Right to Buy) | −242,142 | 0 | ||
| 2023-07-18 | Rimac Anthony M Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +242,142 | 242,142 | ||
| 2023-07-18 | Parsey Merdad Director | Returned to the company | −8,677 | 0 | ||
| 2023-07-18 | Parsey Merdad Director | Grant or award | +8,677 | 8,677 | ||
| 2023-07-18 | Parsey Merdad Director | Conversion | +4,117 | 12,794 | ||
| 2023-07-18 | Parsey Merdad Director | Conversion · Series E Preferred Stock | −327,309 | 0 | ||
| 2023-07-18 | Parsey Merdad Director | Returned to the company · Stock Option (Right to Buy) | −2,086 | 0 | ||
| 2023-07-18 | Parsey Merdad Director | Grant or award · Stock Option (Right to Buy) | +2,086 | 2,086 | ||
| 2023-07-18 | Parsey Merdad Director | Returned to the company · Stock Option (Right to Buy) | −3,349 | 0 | ||
| 2023-07-18 | Parsey Merdad Director | Grant or award · Stock Option (Right to Buy) | +3,349 | 3,349 | ||
| 2023-07-18 | Parsey Merdad Director | Returned to the company · Stock Option (Right to Buy) | −144 | 0 | ||
| 2023-07-18 | Parsey Merdad Director | Grant or award · Stock Option (Right to Buy) | +144 | 144 |
Page 8 of 10 · 194 trades